Short Bowel Syndrome Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Short Bowel Syndrome Market Trends and Insights

Rising Prevalence of SBS & Complex GI Surgeries

Neonatal surgical advances have lifted survival in very low birth-weight infants, yet they have also pushed neonatal SBS incidence to 22.1 per 1,000 NICU admissions in recent cohorts ^{[1] Journal of Pediatric Surgery Editorial Board, “Short Bowel Syndrome Epidemiology,” sciencedirect.com}. Adult incidence is rising for similar reasons: oncologic and inflammatory bowel resections are now more radical, preserving life but shortening bowel length. CMS coding changes in 2023 created visibility for these additional cases, encouraging earlier referrals and stimulating demand for novel therapeutics. 

Accelerated Approvals & Uptake of GLP-2 Analogs

The FDA expanded teduglutide to children aged ≥1 year and granted fast-track status to newer molecules such as apraglutide and sonefpeglutide, creating a virtuous cycle of innovation and access. Takeda’s Gattex/Revestive posted JPY 119.3 billion sales in fiscal 2024, up 28.1% year over year ^{[2]Takeda Pharmaceutical Company Limited, “FY 2024 Full-Year Results,” takeda.com}. Conversely, Zealand Pharma’s glepaglutide received a Complete Response Letter in December 2024, highlighting the market’s regulatory volatility. 

Orphan-Drug Incentives & Favorable Reimbursement

U.S. Medicare covers home PN under Part B when strict criteria are met, and advocacy groups are working to update the three-decade-old policy to widen access ^{[3]Oley Foundation Advocacy Team, “Medicare Home PN Coverage,” oley.org}. In Europe, NICE endorsed teduglutide under managed-entry agreements, balancing cost effectiveness with patient need. These incentives enable premium pricing and attract continued investment even as payers demand real-world evidence of PN reduction. 

Global Patient-Registry & NGO Awareness Initiatives

Registries coordinated by ESPEN and foundations such as IFFGD generate longitudinal data on safety and quality of life, expediting regulatory filings and reimbursement reviews. Awareness initiatives in emerging markets are crucial, as clinicians historically under-diagnosed SBS because they lacked dedicated codes or training. 

Tissue-Engineered Intestine R&D Breakthroughs

Tissue-engineered small intestine constructs restored 98% weight recovery in animal models versus 76% for controls. Colonic SATB2 gene knock-out reprogrammed colon tissue toward small-intestinal function, improving nutrient uptake in preclinical studies. Stem-cell organoids now achieve 17% engraftment after 10 weeks, supporting first-in-human trials. 

High Therapy Cost & Limited Access in LMICs

Total annual therapy costs exceed USD 43,000 per patient when factoring PN, monitoring, and complication management. Many LMIC health systems lack reimbursement frameworks or the cold-chain logistics for GLP-2 analogs. Manufacturers are experimenting with tiered pricing, but infrastructure constraints persist, motivating interest in low-cost peptides or simplified PN regimens. 

Serious Long-Term Safety Concerns (e.g., Neoplasia)

GLP-2 analogs mandate baseline and regular colonoscopies because long-term exposure may elevate polyp risk. Hyperamylasemia and hyperlipasemia have also been reported, particularly in pediatric cohorts. Regulators now require extended post-marketing surveillance, raising trial costs and deterring smaller entrants. 

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Drug Class: GLP-2 Dominance Faces Innovation Pressure

GLP-2 analogs accounted for 95.72% of the Short Bowel Syndrome market in 2025, propelled by teduglutide’s robust evidence base. Growth hormone therapies, though smaller in absolute sales, are set for 7.94% CAGR through 2031 as pediatric specialists employ them to spur mucosal adaptation. Weekly and monthly GLP-2 candidates like apraglutide and sonefpeglutide seek to reduce injection burden, whereas OPKO Health and Entera Bio are developing the first oral GLP-2 peptide, a shift that could reposition the Short Bowel Syndrome market size for maintenance therapy. Competitive differentiation now centers on dosing convenience, safety, and incremental PN-reduction data to secure payer acceptance and justify premium prices.

Future uptake will hinge on real-world evidence showing durable PN reduction and manageable colonoscopic surveillance. If next-generation molecules confirm similar efficacy with fewer polyps, the Short Bowel Syndrome market could migrate quickly, fragmenting the current GLP-2 oligopoly. Conversely, any class-wide safety signal could redirect investment toward regenerative or gene-editing modalities.

By Distribution Channel: Hospital Dominance Challenged by Digital Shift

Hospital pharmacies held 55.93% revenue in 2025 because SBS management demands multidisciplinary oversight and sterile compounding. Yet online & others channels are scaling at an 8.51% CAGR as home infusion firms integrate telehealth, IoT-connected pumps, and proactive electrolyte monitoring. Studies show 86% of home PN patients own a connected device, and 63% already engage with health apps. If payers continue rewarding hospital-at-home models, the Short Bowel Syndrome market will distribute more prescriptions through specialty mail-order and digital clinics, shrinking hospital share even as volumes grow.

Retail pharmacies focus on ancillary needs such as antidiarrheals and micronutrient supplements. Their participation could expand if oral GLP-2 formulations succeed, yet stringent cold-chain and counseling requirements still favor specialty or infusion channels today.

By Patient Age Group: Adult Stability Contrasts Pediatric Dynamism

Adult patients made up 84.62% of 2025 revenue because oncologic resections and Crohn-related surgeries are more common in later life. This segment has well-defined protocols and centers of excellence, ensuring predictable penetration for every incremental therapy. However, pediatric cases are climbing fastest, with an 8.72% CAGR, due to improved neonatal survival of premature infants with necrotizing enterocolitis. A systematic review reported 36 children achieving enteral autonomy on teduglutide after 24 weeks, while 149 showed reduced PN needs. Pediatric formulations, weight-based dosing, and family-centric digital support platforms are poised to capture new value pools and diversify the Short Bowel Syndrome market share currently anchored in adult care.

Long-term safety monitoring is more stringent in children, so sponsors must generate lifetime exposure data and collaborate with registries. High efficacy in growth metrics and neurodevelopmental outcomes will be decisive for caregiver adoption and payer endorsement.

Geography Analysis

North America generated 42.05% of the Short Bowel Syndrome market in 2025, supported by specialized intestinal-failure centers, Medicare PN reimbursement, and early access to GLP-2 analogs. CMS coding updates and commercial coverage expansions ensure treatment visibility and financial viability, yet payer criteria remain stringent and require documentation of 12-month PN dependence in some plans.

Europe retains critical mass through centralized care networks and harmonized guidelines. NICE’s commercial arrangement for teduglutide and ESPEN’s multidisciplinary standards provide structure and reduce therapeutic variability. EU clinical consortia also drive first-in-human tissue-engineering trials, strengthening the region’s innovation footprint.

Asia-Pacific is the fastest-growing territory at 8.96% CAGR through 2031, driven by regulatory modernization in China and increased resection volumes tied to rising colorectal cancer incidence. China’s 2023 regulations on special-medical-purpose formula expand access to nutritionally balanced enteral feeds, complementing PN and pharmacotherapy. Japan’s inclusion in global apraglutide trials exemplifies the region’s integration into pivotal studies, accelerating time-to-approval for novel agents.

Regulatory Landscape

Regulation for short bowel syndrome (SBS) therapeutics is shaped by rare-disease pathways, biologics quality requirements, and payer-linked evidence expectations, with GLP-2 analogs as the anchor class. In the United States, teduglutide (GATTEX, Takeda) remains the established GLP-2 option for SBS, and FDA labeling updates (revised prescribing information in September 2025) plus ongoing long-term safety monitoring requirements continue to affect utilization protocols.

In Europe, the European Medicines Agency (EMA) frames access through centralized approvals and post-authorization oversight. In January 2026, EMA marketing authorization for Teduglutide Viatris (positioned as a generic equivalent to Revestive) marked an important regulatory milestone that can affect tender dynamics and price corridors in EU markets, while keeping the same core pharmacovigilance expectations for teduglutide-class products. For pipeline entrants, regulator feedback continues to raise the evidence bar: in April 2025, Ironwood reported FDA feedback requiring a confirmatory Phase 3 trial for apraglutide in SBS with intestinal failure dependent on parenteral support, indicating a tightening standard for new GLP-2 approvals.

Value Chain Analysis

The SBS therapeutics value chain is built around peptide drug development (GLP-2 analogs and adjunct agents), specialized manufacturing, and distribution models tied to intestinal-failure care pathways. Upstream work starts with discovery and clinical development at biopharma sponsors, followed by scale-up and sterile fill-finish for injectable peptides under GMP controls. Manufacturing continuity depends on specialized inputs, including single-use components and peptide production media, as well as qualified sterile filling capacity. Regulatory gating at the manufacturing step, including USP 797 aligned sterile compounding expectations and EMA GMP certification, limits how quickly capacity can shift and reinforces the role of established, quality-accredited facilities.

Downstream, demand generation concentrates around intestinal-failure centers and multidisciplinary prescribers, with procurement routed through hospital pharmacies and specialty infusion networks that support home parenteral nutrition coordination. Specialty distribution and cold-chain logistics remain critical for GLP-2 analogs, and homecare procurement consolidation in major markets has increased negotiating leverage and compressed service margins, pushing manufacturers to bundle patient-support services and real-world evidence generation. Partnerships are a key scaling mechanism across the chain: in June 2026, Eli Lilly signed a USD 1.26 billion licensing agreement with Hanmi to develop, manufacture, and commercialize the long-acting GLP-2 analogue sonefpeglutide for SBS, showing how large-cap entrants use licensing to secure late-stage assets and manufacturing know-how while expanding global commercialization reach.

Market Opportunities and Future Outlook

Opportunities are forming where stakeholders can reduce treatment burden, widen reimbursed access, and improve continuity of care for patients dependent on parenteral support. Long-acting GLP-2 programs create whitespace around dosing convenience and adherence support versus daily injectables, and regulatory engagement is already moving forward for new entrants: Ironwood initiated a rolling NDA submission for apraglutide in February 2026 for adult SBS patients dependent on parenteral support, which signals progress toward additional branded options alongside teduglutide.

Access expansion is also creating near-term commercial headroom through payer and formulary levers rather than new indications alone. In May 2026, Takeda Canada announced that BC PharmaCare added Revestive (teduglutide) to its provincial formulary for eligible pediatric and adult SBS patients, demonstrating how provincial reimbursement decisions can translate into uptake in treated populations. Larger biopharma licensing adds another opportunity vector by combining capital and operational scale: in June 2026, Eli Lilly licensed Hanmi’s sonefpeglutide with global rights outside Korea, which can accelerate global clinical execution and strengthen market education and distribution readiness in territories where SBS diagnosis and specialty infusion infrastructure are still developing.